MP29-02 (Dymista (R)) - a new treatment option for allergic rhinitis.

Introduction: Recent developments in drug research in the indication allergic rhinitis (AR) include the development of new compounds as well as new formulations of substances with synergistic effects. IVIP29-02 (Dymista (R)) is a novel drug for AR treatment consisting of a new intranasal formulation of the antihistamine azelastine hydrochloride (AZE) and the nasal glucocorticoid fluticasone propionate (FP). Methods: Based on a literature review we summarise the results of several clinical trials regarding efficacy and safety of MP29-02 compared to AZE and FP monotherapy and placebo. Results: Compared to AZE, FP, and placebo, MP29-02 has demonstrated a superior efficacy in regard to nasal and ocular symptoms. Patients with moderate-to-severe seasonal allergic rhinitis (SAR) treated with MP29-02 showed an up to 7 days faster response of nasal symptoms than AZE and up to 5 days faster than FP treatment. Also, in patients with chronic rhinitis, MP29-02 significantly improved nasal symptoms compared to the FP therapy. Discussion and conclusion: MP29-02 represents a novel and promising combination for the treatment of AR with superior efficacy over current first line therapies.     «

Introduction: Recent developments in drug research in the indication allergic rhinitis (AR) include the development of new compounds as well as new formulations of substances with synergistic effects. IVIP29-02 (Dymista (R)) is a novel drug for AR treatment consisting of a new intranasal formulation of the antihistamine azelastine hydrochloride (AZE) and the nasal glucocorticoid fluticasone propionate (FP). Methods: Based on a literature review we summarise the results of several clinical trials...     »